AllerGen Research Leader Dr. Paul O’Byrne has been elected a Fellow of the Canadian Academy of Health Sciences (CAHS), one of the highest honours for Canadians in the health sciences community.
“This is an important recognition of Dr. O’Byrne’s academic contribution and leadership, including his leadership in AllerGen,” observes AllerGen’s Board Chair, Dr. Howard Bergman.
In its announcement of his Fellowship status, CAHS characterizes Dr. O’Byrne’s professional accomplishments concisely: “Internationally recognized for seminal contributions into understanding the causes and treatment of asthma, including the first studies of the central role of airway inflammation in its initiation and persistence. His work has explained the mechanisms of allergen-induced inflammatory responses and aided the development of anti-leukotrienes as a new asthma treatment. He has published extensively in the most highly cited peer-review journals. His studies of asthma treatment have influenced treatment guidelines worldwide.”
CAHS Fellows are recognized for their innovative leadership, research excellence and commitment to advancing academic health science. Founded in 2004, the CAHS provides timely, informed and unbiased assessments of urgent issues affecting the health of Canadians.
Read the press release.